Search

Author/Creator Beygi, Hooman

1. Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects. (9th August 2018)

Authors:
Schneider, Frank; Erisson, Lavi; Beygi, Hooman; Bradbury, Margaret; Cohen‐Barak, Orit; Grachev, Igor D.; Guzy, Serge; Loupe, Pippa S.; Levi, Micha; McDonald, Mirna; Savola, Juha‐Matti; Papapetropoulos, Spyros; Tracewell, William G.; Velinova, Maria; Spiegelstein, Ofer
Journal:
British journal of clinical pharmacology
Issue:
Volume 84:Number 10(2018)
Page Start:
2422
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis. Issue 6 (June 2014)

Authors:
Nordstrom, Beth L.; Knopf, Kevin B.; Teltsch, Dana Y.; Engle, Robert; Beygi, Hooman; Sterchele, James A.
Journal:
Leukemia & lymphoma
Issue:
Volume 55:Issue 6(2014:Jun.)
Page Start:
1266
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. (June 2013)

Authors:
Kolibaba, Kathryn S.; Sterchele, James A.; Joshi, Avani D.; Forsyth, Michael; Alwon, Erin; Beygi, Hooman; Kennealey, Gerard T.
Journal:
Therapeutic advances in hematology
Issue:
Volume 4:Number 3(2013)
Page Start:
157
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗